KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Sarepta Therapeutics (SRPT) Net Income towards Common Stockholders (2016 - 2025)

Sarepta Therapeutics has reported Net Income towards Common Stockholders over the past 15 years, most recently at -$282.8 million for Q4 2025.

  • For Q4 2025, Net Income towards Common Stockholders fell 261.75% year-over-year to -$282.8 million; the TTM value through Dec 2025 reached -$709.1 million, down 381.13%, while the annual FY2025 figure was -$713.4 million, 382.83% down from the prior year.
  • Net Income towards Common Stockholders for Q4 2025 was -$282.8 million at Sarepta Therapeutics, down from -$179.9 million in the prior quarter.
  • Over five years, Net Income towards Common Stockholders peaked at $249.3 million in Q4 2021 and troughed at -$516.8 million in Q1 2023.
  • A 5-year average of -$74.6 million and a median of -$44.5 million in 2021 define the central range for Net Income towards Common Stockholders.
  • On a YoY basis, Net Income towards Common Stockholders climbed as much as 2858.75% in 2025 and fell as far as 1324.44% in 2025.
  • Year by year, Net Income towards Common Stockholders stood at $249.3 million in 2021, then plummeted by 42.99% to $142.1 million in 2022, then plummeted by 67.88% to $45.7 million in 2023, then surged by 283.02% to $174.9 million in 2024, then plummeted by 261.75% to -$282.8 million in 2025.
  • Business Quant data shows Net Income towards Common Stockholders for SRPT at -$282.8 million in Q4 2025, -$179.9 million in Q3 2025, and $201.2 million in Q2 2025.